How have YMTX shares performed in 2024?

Yumanity Therapeutics' stock was trading at $3.63 at the beginning of the year. Since then, YMTX stock has decreased by 86.6% and is now trading at $0.4861. View the best growth stocks for 2024 here .

How were Yumanity Therapeutics' earnings last quarter?

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) posted its earnings results on Thursday, August, 12th. The company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by $0.19. The business earned $2.11 million during the quarter, compared to analyst estimates of $2.27 million. Yumanity Therapeutics had a negative trailing twelve-month return on equity of 263.34% and a negative net margin of 660.61%.

How do I buy shares of Yumanity Therapeutics?

Shares of YMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:YMTX

Yumanity Therapeutics (YMTX) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

Free YMTX Stock Alerts

$0.49

+0.02 (+4.29%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.41
▼
$0.55
50-Day Range: $0.34
▼
$2.83
52-Week Range: $0.95
▼
$13.23

Volume: 848,743 shs
Average Volume: 473,083 shs
Market Capitalization: $5.28 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Insider Trades SEC Filings Social Media

Get Yumanity Therapeutics alerts:

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Yumanity Therapeutics Stock (NASDAQ:YMTX)

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

YMTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

YMTX Stock News Headlines

March 20, 2024 | seekingalpha.com

JSPR Jasper Therapeutics, Inc.

November 3, 2023 | morningstar.com

Cara Therapeutics Inc CARA

April 19, 2024 | Darwin (Ad)

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)

October 6, 2023 | thestreet.com

Yumanity Therapeutics Inc.

July 5, 2023 | thestreet.com

Former Onyx CEO Returns to Biotech to Launch Boston Start Up

May 1, 2023 | bizjournals.com

Kineta raises $6M through registered direct offering

February 22, 2023 | finance.yahoo.com

Colorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus Reports

December 26, 2022 | msn.com

Yumanity Therapeutics's Return On Capital Employed Insights

April 19, 2024 | Darwin (Ad)

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

December 20, 2022 | bizjournals.com

Kineta finalizes reverse merger with Yumanity, secures additional funding

December 5, 2022 | finance.yahoo.com

Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta

December 5, 2022 | investorplace.com

Why Is Yumanity Therapeutics (YMTX) Stock Up Today?

November 14, 2022 | finanznachrichten.de

Yumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 14, 2022 | finance.yahoo.com

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 10, 2022 | finance.yahoo.com

Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.

August 29, 2022 | finance.yahoo.com

Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta

August 4, 2022 | finance.yahoo.com

Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

June 8, 2022 | finance.yahoo.com

Inside Kineta's plans after unveiling reverse merger deal

June 7, 2022 | bizjournals.com

Seattle biotech Kineta to go public in merger deal with Yumanity Therapeutics

June 7, 2022 | msn.com

Short Volatility Alert: Yumanity Therapeutics, Inc.

June 6, 2022 | marketwatch.com

Yumanity to Sell Neurosciences Candidates, Merge With Kineta >YMTX

June 6, 2022 | seekingalpha.com

Yumanity stock soars 46% on all-stock merger with Kineta; lead product sale to J&J for $26M

June 6, 2022 | nasdaq.com

Yumanity Therapeutics To Sell 2 Product Candidates For $26 Mln In Cash; Inks Merger Deal With Kineta

June 6, 2022 | finance.yahoo.com

Yumanity Therapeutics Shares Trading Higher Today - Read Here Why

June 6, 2022 | investorplace.com

Why Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?

June 6, 2022 | finance.yahoo.com

Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions

June 2, 2022 | benzinga.com

53 Stocks Moving In Thursday's Mid-Day Session

See More Headlines

Receive YMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/12/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:YMTX
CUSIP: N/A
CIK: 1445283
Web: www.yumanity.com
Phone: (617) 409-5300
Fax: N/A
Employees: 40
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-39,500,000.00
Net Margins: -660.61%
Pretax Margin: -660.61%
Return on Equity: -263.34%
Return on Assets: -107.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.21
Quick Ratio: 2.21

Sales & Book Value

Annual Sales: $4.84 million
Price / Sales: 1.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.28 per share
Price / Book: 0.21

Miscellaneous

Outstanding Shares: 10,856,000
Free Float: 9,504,000
Market Cap: $5.28 million
Optionable: Not Optionable
Beta: 0.32

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Richard Peters M.D. (Age 59)
Ph.D., CEO, Pres & Director
Comp: $896.1k
Dr. Vikram Khurana M.D.
Ph.D., Scientific Co-Founder & Sr. Advisor of Discovery Biology
Ms. Chee Yeun Chung Ph.D.
Scientific Co-Founder & Associate Director of Discovery Biology
Ms. Marie Epstein CPA
VP of Fin.
Mr. Michael D. Wyzga (Age 33)
SVP, CFO & Treasurer
Mr. Devin Whittemore Smith (Age 54)
SVP, Gen. Counsel & Sec.

Key Competitors

View All Competitors

YMTX Stock Analysis - Frequently Asked Questions

How have YMTX shares performed in 2024?: Yumanity Therapeutics' stock was trading at $3.63 at the beginning of the year. Since then, YMTX stock has decreased by 86.6% and is now trading at $0.4861.
View the best growth stocks for 2024 here.
How were Yumanity Therapeutics' earnings last quarter?: Yumanity Therapeutics, Inc. (NASDAQ:YMTX) posted its earnings results on Thursday, August, 12th. The company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by $0.19. The business earned $2.11 million during the quarter, compared to analyst estimates of $2.27 million. Yumanity Therapeutics had a negative trailing twelve-month return on equity of 263.34% and a negative net margin of 660.61%.
How do I buy shares of Yumanity Therapeutics?: Shares of YMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:YMTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial